SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Arthur Klausner will sit on a panel at the 11th Annual Drug Delivery Technologies and Deal Making Conference, sponsored by SRI
News | 09. 26. 2006
